Delivery Order SPE2DB20D1109-SPE2DB25FP11K

Award Date 5/22/25
Potential Completion Date 5/23/25
Potential Value $6.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,337.97 firm-fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to supply 10mg Vyvanse capsules. The contract has a completion date of September 20, 2024 and was awarded on September 19, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a wide...
This is a $2,229.50 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for 4,567,299,098 units of the drug Vyvanse 10 mg capsules. The contract has a period of performance through February 7, 2025 and was not designated as a set-aside. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a $2,339.62 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) on July 2, 2025. The order is for 100 units of the medication Vyvanse 50 mg capsules. The contract has an ultimate completion date of July 3, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
This is a $1,337.70 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) to supply 100 units of the medication Vyvanse 60 mg capsules. The contract has a completion date of June 25, 2025 and is not set aside for any particular business type. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This is a $10,360.38 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to supply 4,565,712,508 units of the prescription drug Vyvanse 30mg capsules. The order has a completion date of September 9, 2024. This delivery order is a part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,737.44, is for the delivery of 100 units of the medication Vyvanse 30 mg capsule. The contract has an ultimate completion date of April 23, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
This is a $1,404.05 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 100 units of the prescription medication Vyvanse 40 mg capsules. The contract has an ultimate completion date of June 30, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,135.65 firm fixed-price contract is for the delivery of 100 units of the prescription medication Vyvanse 50 mg capsules. The contract has a performance period ending on June 24, 2025. This delivery order is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp with the...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 100 units of 20 mg Vyvanse capsules. The contract has a firm fixed price of $2,946.08 and a completion date of June 18, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 held by AmerisourceBergen with the DLA, which provides a comprehensive global pharmaceutical...
The U.S. Defense Logistics Agency (DLA) awarded a $1,783.60 firm-fixed-price delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 100 units of the medication Vyvanse 30 mg capsules. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which covers a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB25FP11K
    Delivery Order

This is a $6,261.36 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 100 units of the drug Vyvanse 30 mg capsules. The contract has a period of performance ending on May 23, 2025. This order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a performance period through December 2026. The contract is not designated as a set-aside.

Generated 8/21/25, 10:02 AM